Metin Kurtoglu sold $649k of RNAC
Chief Technology Officer at Cartesian Therapeutics, Inc.. 38,689 shares at an average of $16.78, traded Nov 19, 2024, filed Nov 21, 2024.
Score components
- +15RoleOfficer
- +20Trade size$649k at market
- +20Share of holdings soldSold 76% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +14.4%, 3m +18.0%, 6m -45.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001453687-24-000140, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | MOption exercise Common Stock | +200 | $1.41 | $282 | 51,233 | Nov 21, 2024 |
| Nov 19, 2024 | SOpen-market sale Common Stock | -200 | $19.50 | $3,900 | 51,033 | Nov 21, 2024 |
| Nov 20, 2024 | MOption exercise Common Stock | +5,700 | $1.41 | $8,037 | 56,733 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock | -5,600 | $17.28 | $97k | 51,133 | Nov 21, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Stock | -100 | $18.09 | $1,809 | 51,033 | Nov 21, 2024 |
| Nov 21, 2024 | MOption exercise Common Stock | +32,789 | $1.41 | $46k | 83,822 | Nov 21, 2024 |
| Nov 21, 2024 | SOpen-market sale Common Stock | -32,789 | $16.67 | $547k | 51,033 | Nov 21, 2024 |
| Nov 19, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -200 | - | - | 131,252 | Nov 21, 2024 |
| Nov 20, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -5,700 | - | - | 125,552 | Nov 21, 2024 |
| Nov 21, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -32,789 | - | - | 92,763 | Nov 21, 2024 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $162k 23,766 shares | -7% | |
| 45Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $72k 10,591 shares | -8% | |
| 30Weak | Cartesian Therapeutics, Inc. | Milos Miljkovic Chief Medical Officer | $24k 3,573 shares | -6% | |
| 55Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy C Barabe director | $206k 30,000 shares | +123% | |
| 53Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.5M 149,075 shares | +2% | |
| 45Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.4M 89,863 shares | +1% | |
| 30Weak | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $366k 20,967 shares | +0% | |
| 54Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $290k 17,271 shares | -8% | |
| 48Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $134k 7,989 shares | -8% | |
| 40Moderate | Cartesian Therapeutics, Inc. | Emily English Chief Operations Officer | $30k 1,797 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.